StocksMedium•5 November 2026•
1 min read
Niagen Bioscience Reports Q3 Loss, Misses Revenue Estimates
Key Facts
1Niagen Bioscience reported a quarterly loss of $0.01 per share, which was in line with the Zacks Consensus Estimate.
2The company's results declined compared to a year ago when it reported earnings of $0.05 per share.
Niagen Bioscience reported a quarterly loss of $0.01 per share for its third-quarter financial results ending September 2026. Zacks reported that the figure was in line with analyst consensus estimates, though it represents a decline from the $0.05 per share profit recorded in the same period last year.
NAGE closed at $2.52 on November 4, 2026, with the session seeing a trading range between a low of $2.4 and a high of $2.59. The results highlight a year-over-year transition from profit to loss alongside a miss on revenue expectations.